Mar 13 |
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
|
Mar 6 |
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
|
Mar 4 |
EDAP Announces FDA Breakthrough Device Designation for Focal OneĀ® in the Treatment of Deep Infiltrating Rectal Endometriosis
|
Feb 29 |
EDAP TMS S.A. reports Q4 results
|
Feb 29 |
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
|
Feb 1 |
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
|
Jan 8 |
EDAP announces preliminary Q4 record Focal One system sales and placements
|
Jan 8 |
EDAP Announces Preliminary Fourth Quarter Record Focal OneĀ® System Sales and Placements
|
Jan 2 |
EDAP TMS appoints CFO, chief accounting officer
|
Jan 2 |
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
|